{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:48:30Z","timestamp":1789645710257,"version":"4.0.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11897-016-0295-7","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T09:01:04Z","timestamp":1465462864000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure"],"prefix":"10.1007","volume":"13","author":[{"given":"Justin L.","family":"Grodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"295_CR1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","volume":"65","author":"F Verbrugge","year":"2015","unstructured":"Verbrugge F, Steels P, Grieten L, Nijst P, Tang Wh And Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65:480\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00392-015-0896-2","volume":"105","author":"J Maaten Ter","year":"2016","unstructured":"Ter Maaten J, Valente M, Metra M, Bruno N, O\u2019connor C, Ponikowski P, et al. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clin Res Cardiol. 2016;105:145\u201353.","journal-title":"Clin Res Cardiol"},{"key":"295_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, Mcmurray J, Swedberg K, Krum H, Van Veldhuisen D, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the eplerenone in mild patients hospitalization and survival study in heart failure (emphasis-HF). Circ Heart Fail. 2014;7:51\u20138.","journal-title":"Circ Heart Fail"},{"key":"295_CR4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai A, Zannad F, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7:573\u20139.","journal-title":"Circ Heart Fail"},{"key":"295_CR5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","volume":"115","author":"S Khan","year":"2015","unstructured":"Khan S, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni A, et al. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the Everest trial). Am J Cardiol. 2015;115:790\u20136.","journal-title":"Am J Cardiol"},{"key":"295_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.01.007","author":"L Cooper","year":"2016","unstructured":"Cooper L, Mentz R, Gallup D, Lala A, Devore A, Vader J, et al. Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail. 2016. doi: 10.1016\/j.cardfail.2016.01.007 .","journal-title":"J Card Fail"},{"key":"295_CR7","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"L Klein","year":"2005","unstructured":"Klein L, O\u2019connor C, Leimberger J, Gattis-Stough W, Pina I, Felker G, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (optime-CHF) study. Circulation. 2005;111:2454\u201360.","journal-title":"Circulation"},{"key":"295_CR8","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","volume":"167","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Rossi J, Cotts W, Shin D, Hellkamp A, Pina I, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the escape trial. Arch Intern Med. 2007;167:1998\u20132005.","journal-title":"Arch Intern Med"},{"key":"295_CR9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacc.2015.06.007","volume":"66","author":"J Grodin","year":"2015","unstructured":"Grodin J, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, et al. Prognostic role of serum chloride levels in acute decompensated heart failure. J Am Coll Cardiol. 2015;66:659\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR10","doi-asserted-by":"crossref","first-page":"E002453","DOI":"10.1161\/CIRCHEARTFAILURE.115.002453","volume":"9","author":"J Grodin","year":"2016","unstructured":"Grodin J, Verbrugge F, Ellis S, Mullens W, Testani J, Tang W. Importance of abnormal chloride homeostasis in stable chronic heart failure. Circ Heart Fail. 2016;9:E002453.","journal-title":"Circ Heart Fail"},{"key":"295_CR11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijcard.2009.04.041","volume":"144","author":"M Ahmed","year":"2010","unstructured":"Ahmed M, Ekundayo O, Mujib M, Campbell R, Sanders P, Pitt B, et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010;144:383\u20138.","journal-title":"Int J Cardiol"},{"key":"295_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.477","author":"J Testani","year":"2016","unstructured":"Testani J, Hanberg J, Arroyo J, Brisco M, Ter Maaten J, Wilson F, et al. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. Eur J Heart Fail. 2016. doi: 10.1002\/ejhf.477 .","journal-title":"Eur J Heart Fail"},{"key":"295_CR13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt B, Bakris G, Ruilope LM, Dicarlo L, Mukherjee R, Investigators E. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (Ephesus). Circulation. 2008;118:1643\u201350.","journal-title":"Circulation"},{"key":"295_CR14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000377669","volume":"131","author":"N Khan","year":"2015","unstructured":"Khan N, Nabeel M, Nan B, Ghali J. Chloride depletion alkalosis as a predictor of inhospital mortality in patients with decompensated heart failure. Cardiology. 2015;131:151\u20139.","journal-title":"Cardiology"},{"key":"295_CR15","doi-asserted-by":"crossref","first-page":"E240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"C Yancy","year":"2013","unstructured":"Writing Committee M, Yancy C, Jessup M, Bozkurt B, Butler J, De Jr C, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:E240\u2013327.","journal-title":"Circulation"},{"key":"295_CR16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"J Mcmurray","year":"2012","unstructured":"Mcmurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803\u201369.","journal-title":"Eur J Heart Fail"},{"key":"295_CR17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.111.065391","volume":"125","author":"K Cp","year":"2012","unstructured":"Cp K, Lott E, Lu J, Sm M, Ma J, Molnar M, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125:677\u201384.","journal-title":"Circulation"},{"key":"295_CR18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jchf.2014.04.008","volume":"2","author":"K Rahimi","year":"2014","unstructured":"Rahimi K, Bennett D, Conrad N, Williams T, Basu J, Dwight J, et al. Risk prediction in patients with heart failure: a systematic review and analysis. Jacc Heart Fail. 2014;2:440\u20136.","journal-title":"Jacc Heart Fail"},{"key":"295_CR19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/000331979004100807","volume":"41","author":"C Panciroli","year":"1990","unstructured":"Panciroli C, Galloni G, Oddone A, Marangoni E, Masa A, Cominesi W, et al. Prognostic value of hyponatremia in patients with severe chronic heart failure. Angiology. 1990;41:631\u20138.","journal-title":"Angiology"},{"key":"295_CR20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","volume":"170","author":"R Wald","year":"2010","unstructured":"Wald R, Jaber B, Price L, Upadhyay A, Madias N. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170:294\u2013302.","journal-title":"Arch Intern Med"},{"key":"295_CR21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","volume":"28","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Abraham W, Albert N, Gattis Stough W, Greenberg B, O\u2019connor C, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the optimize-HF registry. Eur Heart J. 2007;28:980\u20138.","journal-title":"Eur Heart J"},{"key":"295_CR22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cardfail.2012.06.415","volume":"18","author":"M Konishi","year":"2012","unstructured":"Konishi M, Haraguchi G, Ohigashi H, Sasaoka T, Yoshikawa S, Inagaki H, et al. Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. J Card Fail. 2012;18:620\u20135.","journal-title":"J Card Fail"},{"key":"295_CR23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCHEARTFAILURE.112.000106","volume":"6","author":"D Shchekochikhin","year":"2013","unstructured":"Shchekochikhin D, Schrier R, Lindenfeld J, Price L, Jaber B, Madias N. Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure. Circ Heart Fail. 2013;6:379\u201386.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"295_CR24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.amjmed.2016.01.016","volume":"129","author":"F Verbrugge","year":"2016","unstructured":"Verbrugge F, Grodin J, Mullens W, Taylor D, Starling R, Tang W. Transient hyponatremia during hospitalization for acute heart failure. Am J Med. 2016;129(6):620\u20137.","journal-title":"Am J Med"},{"key":"295_CR25","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","volume":"342","author":"H Adrogue","year":"2000","unstructured":"Adrogue H, Madias N. Hyponatremia. N Engl J Med. 2000;342:1581\u20139.","journal-title":"N Engl J Med"},{"key":"295_CR26","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"S Goldsmith","year":"1983","unstructured":"Goldsmith S, Francis G, Aw Jr C, Levine T, Cohn J. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR27","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"F Gs","year":"1990","unstructured":"Gs F, Benedict C, Johnstone D, Kirlin P, Nicklas J, Liang C, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724\u20139.","journal-title":"Circulation"},{"key":"295_CR28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01063938","volume":"396","author":"R Greger","year":"1983","unstructured":"Greger R, Schlatter E. Properties of the basolateral membrane of the cortical thick ascending limb of Henle\u2019s loop of rabbit kidney. A model for secondary active chloride transport. Pflugers Arch. 1983;396:325\u201334.","journal-title":"Pflugers Arch"},{"key":"295_CR29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1006\/geno.1996.0388","volume":"35","author":"N Mastroianni","year":"1996","unstructured":"Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, et al. Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (Slc12a3). Genomics. 1996;35:486\u201393.","journal-title":"Genomics"},{"key":"295_CR30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ejhf.35","volume":"16","author":"F Verbrugge","year":"2014","unstructured":"Verbrugge F, Dupont M, Steels P, Grieten L, Swennen Q, Tang W, et al. The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?\u2019. Eur J Heart Fail. 2014;16:133\u201342.","journal-title":"Eur J Heart Fail"},{"key":"295_CR31","first-page":"83","volume":"32","author":"U Kreimeier","year":"1990","unstructured":"Kreimeier U, Bruckner U, Niemczyk S, Messmer K. Hyperosmotic saline dextran for resuscitation from traumatic-hemorrhagic hypotension: effect on regional blood flow. Circ Shock. 1990;32:83\u201399.","journal-title":"Circ Shock"},{"key":"295_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1590\/S1516-31801995000600008","volume":"113","author":"A Monteiro Pacheco Jr","year":"1995","unstructured":"Monteiro Pacheco Jr A, Martins Coimbra R, Kreimeier U, Frey L, Messmer K. Hypertonic volume therapy: feasibility in the prevention and treatment of multiple organ failure and sepsis. Sao Paulo Med J. 1995;113:1053\u201360.","journal-title":"Sao Paulo Med J"},{"key":"295_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(00)00094-5","volume":"2","author":"S Paterna","year":"2000","unstructured":"Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail. 2000;2:305\u201313.","journal-title":"Eur J Heart Fail"},{"key":"295_CR34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1067\/mhj.2003.166","volume":"145","author":"G Licata","year":"2003","unstructured":"Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459\u201366.","journal-title":"Am Heart J"},{"key":"295_CR35","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2005.01.059","volume":"45","author":"S Paterna","year":"2005","unstructured":"Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005;45:1997\u20132003.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2036.2009.04040.x","volume":"30","author":"G Licata","year":"2009","unstructured":"Licata G, Tuttolomondo A, Licata A, Parrinello G, Di Raimondo D, Di Sciacca R, et al. Clinical trial: high-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther. 2009;30:227\u201335.","journal-title":"Aliment Pharmacol Ther"},{"key":"295_CR37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cardfail.2010.11.003","volume":"17","author":"G Parrinello","year":"2011","unstructured":"Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011;17:331\u20139.","journal-title":"J Card Fail"},{"key":"295_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ahj.2012.05.025","volume":"164","author":"G Parrinello","year":"2012","unstructured":"Parrinello G, Di Pasquale P, Torres D, Cardillo M, Schimmenti C, Lupo U, et al. Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-Hss-Fur). Am Heart J. 2012;164:351\u20137.","journal-title":"Am Heart J"},{"key":"295_CR39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00059-010-3394-3","volume":"36","author":"R Vecchis De","year":"2011","unstructured":"De Vecchis R, Ciccarelli A, Ariano C, Pucciarelli A, Cioppa C, Giasi A, et al. Renoprotective effect of small volumes of hypertonic saline solution in chronic heart failure patients with marked fluid retention: results of a case-control study. Herz. 2011;36:12\u20137.","journal-title":"Herz"},{"key":"295_CR40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S0066-782X2007001600007","volume":"89","author":"V Issa","year":"2007","unstructured":"Issa V, Bacal F, Mangini S, Carneiro R, Azevedo C, Chizzola P, et al. Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure. Arq Bras Cardiol. 2007;89:251\u20135.","journal-title":"Arq Bras Cardiol"},{"key":"295_CR41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2011.11.087","volume":"167","author":"V Issa","year":"2013","unstructured":"Issa V, Andrade L, Ayub-Ferreira S, Bacal F, De Braganca A, Guimaraes G, et al. Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure. Int J Cardiol. 2013;167:34\u201340.","journal-title":"Int J Cardiol"},{"key":"295_CR42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00059-013-4041-6","volume":"40","author":"R Vecchis De","year":"2015","unstructured":"De Vecchis R, Esposito C, Ariano C, Cantatrione S. Hypertonic saline plus I.V. Furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: a meta-analysis of the literature. Herz. 2015;40:423\u201335.","journal-title":"Herz"},{"issue":"4","key":"295_CR43","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archinte.1925.00120160088004","volume":"36","author":"H Crawford","year":"1925","unstructured":"Crawford H, Mcintosh J. The use of urea as a diuretic in advanced heart failure. Arch Intern Med (Chic). 1925;36(4):530\u201341.","journal-title":"Arch Intern Med (Chic)"},{"key":"295_CR44","first-page":"924","volume":"60","author":"S Jf","year":"1966","unstructured":"Jf S, Ellison E, Carey L. Osmolar diuresis: success and\/or failure. A collective review. Surgery. 1966;60:924\u201337.","journal-title":"Surgery"},{"key":"295_CR45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.1956.02960460021006","volume":"160","author":"M Javid","year":"1956","unstructured":"Javid M, Settlage P. Effect of urea on cerebrospinal fluid pressure in human subjects; preliminary report. J Am Med Assoc. 1956;160:943\u20139.","journal-title":"J Am Med Assoc"},{"key":"295_CR46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jama.1980.03310060045024","volume":"244","author":"G Decaux","year":"1980","unstructured":"Decaux G, Unger J, Mockel J. Urea therapy for inappropriate antidiuretic hormone secretion from tuberculous meningitis. Jama. 1980;244:589\u201390.","journal-title":"Jama"},{"key":"295_CR47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0002-9343(80)90506-9","volume":"69","author":"G Decaux","year":"1980","unstructured":"Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980;69:99\u2013106.","journal-title":"Am J Med"},{"key":"295_CR48","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.283.6299.1081","volume":"283","author":"G Decaux","year":"1981","unstructured":"Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed). 1981;283:1081\u20133.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"295_CR49","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/bmj.290.6484.1782","volume":"290","author":"G Decaux","year":"1985","unstructured":"Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. Br Med J (Clin Res Ed). 1985;290:1782\u20133.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"295_CR50","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/ndt\/gfm138","volume":"22","author":"A Soupart","year":"2007","unstructured":"Soupart A, Schroeder B, Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrol Dial Transplant. 2007;22:1856\u201363.","journal-title":"Nephrol Dial Transplant"},{"key":"295_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(99)00379-9","volume":"376","author":"T Yatsu","year":"1999","unstructured":"Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, et al. Cardiovascular and renal effects of conivaptan hydrochloride (Ym087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol. 1999;376:239\u201346.","journal-title":"Eur J Pharmacol"},{"key":"295_CR52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(97)00324-6","volume":"38","author":"A Tahara","year":"1998","unstructured":"Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, et al. Effect of Ym087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res. 1998;38:198\u2013205.","journal-title":"Cardiovasc Res"},{"key":"295_CR53","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"J Udelson","year":"2001","unstructured":"Udelson J, Smith W, Hendrix G, Painchaud C, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V(1a) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417\u201323.","journal-title":"Circulation"},{"key":"295_CR54","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"S Rw","year":"2006","unstructured":"Rw S, Gross P, Gheorghiade M, Berl T, Verbalis J, Czerwiec F, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"295_CR55","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","volume":"97","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M, Gottlieb S, Udelson J, Konstam M, Czerwiec F, Ouyang J, et al. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97:1064\u20137.","journal-title":"Am J Cardiol"},{"key":"295_CR56","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam M, Jc Jr B, Grinfeld L, Maggioni A, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the Everest clinical status trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"295_CR57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","volume":"14","author":"S Goldsmith","year":"2008","unstructured":"Goldsmith S, Elkayam U, Haught W, Barve A, He W. Efficacy and safety of the vasopressin V1a\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641\u20137.","journal-title":"J Card Fail"},{"key":"295_CR58","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","volume":"52","author":"J Udelson","year":"2008","unstructured":"Udelson J, Orlandi C, Ouyang J, Krasa H, Zimmer C, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR59","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2011.02.027","volume":"161","author":"P Pang","year":"2011","unstructured":"Pang P, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni A, et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (Everest) trials. Am Heart J. 2011;161:1067\u201372.","journal-title":"Am Heart J"},{"key":"295_CR60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","volume":"6","author":"D Lanfear","year":"2013","unstructured":"Lanfear D, Sabbah Hn Sr G, Greene S, Ambrosy A, Fought A, Kwasny M, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the Everest trial. Circ Heart Fail. 2013;6:47\u201352.","journal-title":"Circ Heart Fail"},{"key":"295_CR61","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","volume":"19","author":"P Hauptman","year":"2013","unstructured":"Hauptman P, Burnett J, Gheorghiade M, Grinfeld L, Konstam M, Kostic D, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail. 2013;19:390\u20137.","journal-title":"J Card Fail"},{"key":"295_CR62","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cardfail.2011.08.012","volume":"17","author":"G Sr","year":"2011","unstructured":"Sr G, Gilbertson D, Mackedanz S, Swan S. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011;17:982\u20139.","journal-title":"J Card Fail"},{"key":"295_CR63","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","volume":"17","author":"J Udelson","year":"2011","unstructured":"Udelson J, Bilsker M, Hauptman P, Sequeira R, Thomas I, O\u2019brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17:973\u201381.","journal-title":"J Card Fail"},{"key":"295_CR64","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis W, O\u2019connor C, Kf Jr A, Elkayam U, Barbagelata A, et al. Acute and chronic therapeutic impact of a vasopressin antagonist in congestive heart failure I. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963\u201371.","journal-title":"JAMA"},{"key":"295_CR65","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"C-B Lc","year":"2006","unstructured":"Lc C-B, Wb S, Boerrigter G, Ouyang J, Zimmer C, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"295_CR66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCHEARTFAILURE.115.002259","volume":"8","author":"G Felker","year":"2015","unstructured":"Felker G, Mentz R, Adams K, Cole R, Egnaczyk G, Patel C, et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the tactics and the secret of CHF trials. Circ Heart Fail. 2015;8:997\u20131005.","journal-title":"Circ Heart Fail"},{"key":"295_CR67","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1172\/JCI111211","volume":"73","author":"J Galla","year":"1984","unstructured":"Galla J, Dn B, Dumbauld S, Luke R. Segmental chloride and fluid handling during correction of chloride-depletion alkalosis without volume expansion in the rat. J Clin Invest. 1984;73:96\u2013106.","journal-title":"J Clin Invest"},{"key":"295_CR68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/01.CIR.21.3.332","volume":"21","author":"R Al","year":"1960","unstructured":"Al R, Spritz N, Mead A, Herrmann R, Braveman W, Luckey E. The use of L-lysine monomydrochloride in combination with mercurial diuretics in the treatment of refractory fluid retention. Circulation. 1960;21:332\u20136.","journal-title":"Circulation"},{"key":"295_CR69","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2012.10.028","volume":"61","author":"A Peixoto","year":"2013","unstructured":"Peixoto A, Alpern R. Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis. 2013;61:822\u20137.","journal-title":"Am J Kidney Dis"},{"key":"295_CR70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00584122","volume":"388","author":"C Yl","year":"1980","unstructured":"Yl C. Adrenergic control of bicarbonate absorption in the proximal convoluted tubule of the rat kidney. Pflugers Arch. 1980;388:159\u201364.","journal-title":"Pflugers Arch"},{"key":"295_CR71","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/archinte.1987.00370120147026","volume":"147","author":"S Voyce","year":"1987","unstructured":"Voyce S, Goldfine H, Gore J. Severe metabolic and respiratory alkalosis associated with the treatment of congestive heart failure. Arch Intern Med. 1987;147:2211\u20132.","journal-title":"Arch Intern Med"},{"key":"295_CR72","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.ajkd.2009.11.028","volume":"55","author":"G Fj","year":"2010","unstructured":"Fj G, Hussain-Khan S, Segal A. An unusual case of metabolic alkalosis: a window into the pathophysiology and diagnosis of this common acid-base disturbance. Am J Kidney Dis. 2010;55:1130\u20135.","journal-title":"Am J Kidney Dis"},{"key":"295_CR73","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ijcard.2014.09.166","volume":"177","author":"M Nassif","year":"2014","unstructured":"Nassif M, Novak E, Rich M. Association of serum bicarbonate with long-term outcomes in patients hospitalized with heart failure. Int J Cardiol. 2014;177:673\u20135.","journal-title":"Int J Cardiol"},{"key":"295_CR74","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1172\/JCI102702","volume":"31","author":"C Friedberg","year":"1952","unstructured":"Friedberg C, Halpern M, Taymor R. The effect of intravenously administered 6063, the carbonic anhydrase inhibitor, 2-acetylamino-1, 3, 4-thiadiazole-5-sulfonamide, on fluid and electrolytes in normal subjects and patients with congestive heart failure. J Clin Invest. 1952;31:1074\u201381.","journal-title":"J Clin Invest"},{"key":"295_CR75","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM195305212482102","volume":"248","author":"F Ck","year":"1953","unstructured":"Ck F, Taymor R, Minor J, Halpern M. The use of diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure. N Engl J Med. 1953;248:883\u20139.","journal-title":"N Engl J Med"},{"key":"295_CR76","first-page":"883","volume":"123","author":"K Mi","year":"1980","unstructured":"Mi K. Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J. 1980;123:883\u20137.","journal-title":"Can Med Assoc J"},{"key":"295_CR77","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00005344-199703000-00010","volume":"29","author":"H Knauf","year":"1997","unstructured":"Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29:367\u201372.","journal-title":"J Cardiovasc Pharmacol"},{"key":"295_CR78","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cardfail.2014.01.007","volume":"20","author":"A Apostolo","year":"2014","unstructured":"Apostolo A, Agostoni P, Contini M, Antonioli L, Swenson E. Acetazolamide and inhaled carbon dioxide reduce periodic breathing during exercise in patients with chronic heart failure. J Card Fail. 2014;20:278\u201388.","journal-title":"J Card Fail"},{"key":"295_CR79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/AC.70.3.3080630","volume":"70","author":"F Verbrugge","year":"2015","unstructured":"Verbrugge F, Dupont M, Bertrand P, Nijst P, Penders J, Dens J, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70:265\u201373.","journal-title":"Acta Cardiol"},{"key":"295_CR80","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","volume":"97","author":"N Brown","year":"1998","unstructured":"Brown N, Vaughan D. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411\u201320.","journal-title":"Circulation"},{"key":"295_CR81","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2006.05.030","volume":"152","author":"S Denus De","year":"2006","unstructured":"De Denus S, Tardif J, White M, Bourassa M, Racine N, Levesque S, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. Am Heart J. 2006;152:705\u201312.","journal-title":"Am Heart J"},{"key":"295_CR82","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","volume":"148","author":"K Tamirisa","year":"2004","unstructured":"Tamirisa K, Aaronson K, Koelling T. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971\u20138.","journal-title":"Am Heart J"},{"key":"295_CR83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","volume":"158","author":"D Reardon Lc And Macpherson","year":"1998","unstructured":"Reardon Lc And Macpherson D. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26\u201332.","journal-title":"Arch Intern Med"},{"key":"295_CR84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"D Juurlink","year":"2004","unstructured":"Juurlink D, Mamdani M, Lee D, Kopp A, Austin P, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543\u201351.","journal-title":"N Engl J Med"},{"key":"295_CR85","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","volume":"113","author":"R Vl","year":"2013","unstructured":"Vl R. Epidemiology of heart failure. Circ Res. 2013;113:646\u201359.","journal-title":"Circ Res"},{"key":"295_CR86","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjcard.2011.10.027","volume":"109","author":"S Muzzarelli","year":"2012","unstructured":"Muzzarelli S, Maeder M, Toggweiler S, Rickli H, Nietlispach F, Julius B, et al. Frequency and predictors of hyperkalemia in patients >\/=60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol. 2012;109:693\u20138.","journal-title":"Am J Cardiol"},{"key":"295_CR87","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","volume":"50","author":"D As","year":"2007","unstructured":"As D, Swedberg K, Mcmurray J, Granger C, Yusuf S, Young J, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the charm program. J Am Coll Cardiol. 2007;50:1959\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"295_CR88","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"P Bf","year":"2004","unstructured":"Bf P. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585\u201392.","journal-title":"N Engl J Med"},{"key":"295_CR89","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"R Sterns","year":"2010","unstructured":"Sterns R, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21:733\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"295_CR90","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker S, Bushinsky D, Kitzman D, Zannad F, Huang I, et al. Evaluation of the efficacy and safety of Rly5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the pearl-HF) trial. Eur Heart J. 2011;32:820\u20138.","journal-title":"Eur Heart J"},{"key":"295_CR91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"W Mr","year":"2015","unstructured":"Mr W, Gl B, Da B, Mr M, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving Raas inhibitors. N Engl J Med. 2015;372:211\u201321.","journal-title":"N Engl J Med"},{"key":"295_CR92","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"G Bakris","year":"2015","unstructured":"Bakris G, Pitt B, Weir M, Freeman M, Mayo M, Garza D, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the amethyst-DN randomized clinical trial. JAMA. 2015;314:151\u201361.","journal-title":"JAMA"},{"key":"295_CR93","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","volume":"88","author":"A Sr","year":"2015","unstructured":"Sr A, Singh B, Lavin P, Stavros F, Rasmussen H. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, Zs-9, is safe and efficient. Kidney Int. 2015;88:404\u201311.","journal-title":"Kidney Int"},{"key":"295_CR94","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen H, Lavin P, Qunibi W, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the harmonize randomized clinical trial. JAMA. 2014;312:2223\u201333.","journal-title":"JAMA"},{"key":"295_CR95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"P Dk","year":"2015","unstructured":"Dk P, Hs R, Lavin P, Ma E-S, Sd R, Block G, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222\u201331.","journal-title":"N Engl J Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-016-0295-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-016-0295-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-016-0295-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T12:32:19Z","timestamp":1568032339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-016-0295-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s11897-016-0295-7","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}